Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 3, 2009, Pages 245.e1-245.e7

  Ralston Howe, Elizabeth ^a   Li, Zhongze ^b   McGlennen, Ronald C ^c   Hellerstedt, Wendy L ^a   Downs Jr , Levi S ^b,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d Gynecology   (United States)

Author keywords

cervical cancer screening; HPV prevalence; PCR HPV test; type specific HPV persistence

Indexed keywords

ADULT; ARTICLE; BLOOD GROUP TYPING; CANCER SCREENING; CYTODIAGNOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 60849098736     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.10.050     Document Type: Article

References (24)

1. Gerberding J.L. Report to Congress: prevention of genital human papillomavirus infection. Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA (January 2004). http://www.cdc.gov/std/HPV/2004HPV%20Report.pdf Accessed Aug. 15, 2007.
2. Walboomers J.M.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
3. Ho G.Y., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
4. Molano M., Van den B.A., Plummer M., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5 year follow-up study. Am J Epidemiol 158 (2003) 486-494
5. Richardson H., Kelsall G., Tellier P., et al. The natural history of type-specific human papillomavirus infection in female university students. Cancer Epidemiol Biomarkers Prev 12 (2003) 485-490
6. Woodman C.B., Collins S., Winter H., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 (2001) 1831-1836
7. Guiliano A.R., Harris R., Sedjo R.L., et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the young women's health study. J Infect Dis 186 (2002) 462-469
8. Kjaer S., van den Brule A., Paull G., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325 (2002) 572-578
9. Nobbenhuis M.A., Walboomers J.M., Helmershorst T.J., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354 (1999) 20-25
10. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
11. Crosbie E.J., and Kitchener H.C. Human papillomavirus in cervical screening and vaccination. Clin Sci 110 (2006) 543-552
12. Stoler M.H. Advances in cervical screening technology. Mod Path 13 (2000) 275-284
13. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 297 (2007) 813-819
14. Kulmala S.M.A., Shabalova I.P., Petrovitchev N., et al. Type specific persistence of high-risk human papillomavirus infections in the new independent states of the former Soviet Union cohort study. Cancer Epidemiol Biomarkers Prev 16 (2007) 17-22
15. Plummer M., Schiffman M., Castle P.E., et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 195 (2007) 1582-1589
16. Stany M.P., Bidus M.A., Reed E.J., et al. The prevalence of HR-HPV in ASC-US Pap smears: a military population study. Gynecol Oncol 101 (2006) 82-85
17. Resnick R.M., Cornelissen M.T.E., Wright D.K., et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 82 (1990) 1477-1484
18. Lungu O., Wright Jr. T.C., and Silverstein S. Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. Mol Cell Probes 6 (1992) 145-152
19. Franco E.L., Rohan T.E., and Villa L.L. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91 (1999) 506-511
20. Schiffman M., Herrero R., DeSalle R., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337 (2005) 76-84
21. Liaw K.L., Hildesheim A., Burk R.D., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183 (2001) 8-15
22. Sandri M.T., Lentati P., Benini E., et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol 44 (2006) 2141-2146
23. Kulmala S.M., Syrjanen S., Shabalova I., et al. Human papillomavirus testing with the Hybrid Capture 2 Assay and PCR as screening tools. J Clin Microbiol 42 (2004) 2470-2475
24. Gravitt P.E., Peyton C.L., Alessi T.Q., et al. Improved amplification of genital human papillomavirus. J Clin Microbiol 38 (2000) 357-361